Emerging tyrosine kinase inhibitors for head and neck cancer.

ABSTRACT:

Introduction

Conventional regimens for head and neck squamous cell carcinoma (HNSCC) are limited in efficacy and are associated with adverse toxicities. Food and Drug Administration (FDA) approved molecular targeting agents include the HER1 (EGFR)-directed monoclonal antibody cetuximab and the immune checkpoint inhibitors nivolumab and pembrolizumab. However, clinical benefit is only seen in roughly 15-20% of HNSCC patients treated with these agents. New molecular targeting agents are needed that either act with monotherapeutic activity against HNSCC tumors or enhance the activities of current therapies, particularly immunotherapy. Small-molecule tyrosine kinase inhibitors (TKIs) represent a viable option toward this goal.

Areas covered

This review provides an update on TKIs

SUBMITTER: Long Z 

PROVIDER: S-EPMC9987561 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature